N-(1-phenylpropyl)-N-ethylamine | 87876-92-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(1-phenylpropyl)-N-ethylamine
• 英文别名: ethyl-(1-phenyl-propyl)-amine；1-Aethylamino-1-phenyl-propan；Aethyl-(1-phenyl-propyl)-amin；Aethyl-(α-phenyl-propyl)-amin；Ethyl(1-phenylpropyl)amine；N-ethyl-1-phenylpropan-1-amine
• CAS: 87876-92-4
• 化学式: C₁₁H₁₇N
• mdl: MFCD09951075
• 分子量: 163.263
• InChiKey: IFIZHIAVDJBZBY-UHFFFAOYSA-N

物化性质

• 沸点：
  207-208 °C(Press: 729 Torr)
• 密度：
  0.9241 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(1-phenylpropyl)-N-ethylamine 、 2-methoxy-4-chlorobenzoyl thioisocyanate 在 sodium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 丙酮 为溶剂， 生成
  参考文献：
  名称：

  Rational Design, Synthesis, and Structure−Activity Relationships of Aryltriazoles as Novel Corticotropin-Releasing Factor-1 Receptor Antagonists

  摘要：

  Following the discovery of the very high binding affinity of 4-anilinopyrimidines against corticotropin-releasing factor receptor-1 (CRF1) (e.g., 1, K-i = 2 nM), a new series of triazoles bearing different groups has been synthesized and evaluated. The compounds were prepared by cyclizations of N-acyl-S-methylisothioureas with alkylhydrazines or by cyclizations with hydrazine followed by alkylation. While members of this series showed potent binding affinity against CRF1 receptor, there were important differences between the different regio- (7 and 12) and stereoisomeric aryltriazoles where the R-1 or R-2 side chain in 7 has an asymmetric center. In terms of overall potency, aryltriazole analogues such as 7r bearing an N-(alpha-branched benzyl)-N-propylamino side chain were the most potent, followed by analogues such as 7a, with an N-bis(cyclopropyl)methyl-N-propylamino side chain, and analogues such as 7m, with an N-(alpha-branched aliphatic)-N-propylamino side chain. While the N-propyl group was crucial for high potency, we hypothesized that the terminal methyl mimicked the 5-methyl of pyrazolo[1,5-alpha]pyrimidines 3 and 4. Correlation of the low-energy conformers of compounds of type 3 and 7 generated by computational analyses was very good. The size and shape of the N-alkyl group dramatically changed the potency of the triazoles, which is in contrast to the SAR seen for bicyclic CRF1 antagonists. In general, the S-enantiomer was much more potent than the corresponding R-isomer. Furthermore, to a limited extent in the aryltriazole series the substituent on the 5-phenyl ring changed the potency up to 9-fold. (S)-1-Methyl-3-[N-(4-fluorophenylpentyl)-N-propyl]amino-5-(2-methoxy-4-dichlorophenyl)-1H-[1,2,4]triazole [(S)-7r] showed very potent binding affinity (K-i = 2.7 nM) to CRF1 receptors with an IC50 of 49 nM in a cAMP inhibition assay.

  DOI：

  10.1021/jm049339c
• 作为产物：
  描述：

  1,1-二乙氧基-1-苯基丙烷 生成 N-(1-phenylpropyl)-N-ethylamine
  参考文献：
  名称：

  Shiho, Nippon Kagaku Kaishi/Journal of the Chemical Society of Japan, 1947, vol. 68, p. 22

  摘要：

  DOI：

文献信息

• A new synthesis of imidoyl iodides via beckmann rearrangement of oxime sulfonates
  作者：Yasuko Ishida、Satoru Sasatani、Keiji Maruoka、Hisahi Yamamoto

  DOI：10.1016/s0040-4039(00)88149-6

  日期：——

  A new synthetic method of imidoyl iodides has been devised which involves the Beckmann rearrangement of oxime derivatives with trimethylsilyl iodide or diethylaluminum iodide. This allows a one-pot procedure for a α-arylation of amines in synthetically useful yields.

  已经设计出一种新的酰亚胺基碘化物的合成方法，该方法涉及将肟衍生物与三甲基硅烷基碘化物或二乙基铝碘化物进行贝克曼重排。这允许胺的一锅法以合成上有用的产率进行胺的α-芳基化。
• Composition containing a carbonyl amine
  申请人：Cavezza Alexandre

  公开号：US20050008607A1

  公开（公告）日：2005-01-13

  The present invention relates to a composition suitable for topical application to the skin, containing, in a physiologically acceptable medium, at least one carbonyl amine of formula (I): It also relates to the cosmetic use of this compound, especially for preventing or combating the signs of skin ageing, especially for relaxing the lines of the face and/or for smoothing out wrinkles, in particular expression wrinkles. The invention further relates to novel compounds of formula (II):

  本发明涉及一种适用于皮肤局部应用的组合物，其含有至少一种具有化学式(I)的羰基胺，在生理上可接受的介质中。还涉及该化合物的化妆用途，特别是用于预防或对抗皮肤老化迹象，尤其是用于放松面部皱纹和/或平滑皱纹，特别是表情皱纹。该发明还涉及具有化学式(II)的新化合物。
• Cyclin Based Inhibitors of CDK2 and CDK4
  申请人：University of South Carolina

  公开号：US20150011730A1

  公开（公告）日：2015-01-08

  Structural and functional analysis of peptide inhibitor binding to the cyclin D and cyclin A groove has been investigated and used to design peptides that provide the basis for structure-activity relationships, have improved binding and have potential for development as chemical biology probes, as potential diagnostics and as therapeutics in the treatment of proliferative diseases including cancer and inflammation.

  对肽抑制剂与细胞周期素D和细胞周期素A凹槽的结构和功能分析已经进行了研究，并用于设计肽，为结构活性关系提供基础，具有改善结合能力并具有潜力作为化学生物学探针，潜在诊断工具和治疗增生性疾病，包括癌症和炎症。
• PPARG modulators for treatment of osteoporosis
  申请人：The Scripps Research Institute

  公开号：US10016394B2

  公开（公告）日：2018-07-10

  The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.

  本发明提供了治疗进行性骨病（如骨质疏松症、帕吉特氏病、多发性骨髓瘤或甲状旁腺功能亢进症）的方法，包括向患病患者施用有效量的非拮抗剂 PPARG 调节剂。
• The Reaction of Grignard Reagents with Schiff Bases¹
  作者：Kenneth N. Campbell、C. H. Helbing、M. Patricia Florkowski、Barbara K. Campbell

  DOI：10.1021/ja01191a099

  日期：1948.11